144 related articles for article (PubMed ID: 7522874)
1. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours.
Ledermann JA; Holden L; Newlands ES; Begent RH; Rustin GJ; Bagshawe KD; Brampton M
Br J Urol; 1994 Aug; 74(2):225-30. PubMed ID: 7522874
[TBL] [Abstract][Full Text] [Related]
2. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
3. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of two VAB-like regimens (vinblastine + actinomycin-D + bleomycin + cyclophosphamide + cisplatin) in malignant germ cell tumours of the ovary.
Culine S; Lhomme C; Kattan J; Duvillard P; Michel G; Droz JP
Eur J Cancer; 1994; 30A(9):1239-44. PubMed ID: 7528029
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
[TBL] [Abstract][Full Text] [Related]
6. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for ovarian germ cell tumours.
Bower M; Fife K; Holden L; Paradinas FJ; Rustin GJ; Newlands ES
Eur J Cancer; 1996 Apr; 32A(4):593-7. PubMed ID: 8695258
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for non-seminomatous germ-cell tumours.
Wilkinson PM
J R Soc Med; 1985; 78 Suppl 6(Suppl 6):43-7. PubMed ID: 2582119
[No Abstract] [Full Text] [Related]
9. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.
Broun ER; Nichols CR; Gize G; Cornetta K; Hromas RA; Schacht B; Einhorn LH
Cancer; 1997 Apr; 79(8):1605-10. PubMed ID: 9118046
[TBL] [Abstract][Full Text] [Related]
10. POMB/ACE chemotherapy for mediastinal germ cell tumours.
Bower M; Brock C; Holden L; Nelstrop A; Makey AR; Rustin GJ; Newlands ES
Eur J Cancer; 1997 May; 33(6):838-42. PubMed ID: 9291802
[TBL] [Abstract][Full Text] [Related]
11. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG).
Germà-Lluch JR; Garcia del Muro X; Tabernero JM; Sánchez M; Aparicio J; Alba E; Barnadas A
Ann Oncol; 1999 Mar; 10(3):289-93. PubMed ID: 10355572
[TBL] [Abstract][Full Text] [Related]
12. Late relapse of germ cell tumors after cisplatin-based chemotherapy.
Gerl A; Clemm C; Schmeller N; Hentrich M; Lamerz R; Wilmanns W
Ann Oncol; 1997 Jan; 8(1):41-7. PubMed ID: 9093706
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
Tscherry G; Jacky E; Jost LM; Stahel RA
Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
[TBL] [Abstract][Full Text] [Related]
14. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
Culine S; Kattan J; Lhomme C; Duvillard P; Michel G; Castaigne D; Leclere J; Pico J; Droz JP
Gynecol Oncol; 1994 Jul; 54(1):47-53. PubMed ID: 7517380
[TBL] [Abstract][Full Text] [Related]
16. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.
Bower M; Newlands ES; Holden L; Rustin GJ; Begent RH
Ann Oncol; 1997 May; 8(5):477-83. PubMed ID: 9233528
[TBL] [Abstract][Full Text] [Related]
17. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.
Broun ER; Nichols CR; Turns M; Williams SD; Loehrer PJ; Roth BJ; Lazarus HM; Einhorn LH
Cancer; 1994 Mar; 73(6):1716-20. PubMed ID: 7512438
[TBL] [Abstract][Full Text] [Related]
18. Treatment in germ cell tumours: state of the art.
Tjan-Heijnen VC; Oosterhof GO; de Wit R; De Mulder PH
Eur J Surg Oncol; 1997 Apr; 23(2):110-7. PubMed ID: 9158183
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Pituitary Germinoma with Etoposide, Cisplatin, Vincristine, Methotrexate and Bleomycin Chemotherapy Without Radiotherapy.
Scherz A; Feller K; Berezowska S; Genitsch V; Zweifel M
Anticancer Res; 2017 Jun; 37(6):3111-3115. PubMed ID: 28551652
[TBL] [Abstract][Full Text] [Related]
20. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]